Related Experiment Video
Updated: Oct 11, 2025
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
Jin Yuan1, Xiaoyang Li1, Shengji Yu1
1Departments of Orthopedics, 71041National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract:
Soft tissue sarcomas are a form of rare and heterogeneous neoplasms with high recurrence rate and mortality. Over the past decades, less progress has been achieved. Surgical management with or without adjuvant/neoadjuvant radiotherapy is still the first-line treatment for localized soft tissue sarcomas, and chemotherapy is the additional option for those with high-risk. However, not all patients with advanced or metastatic soft tissue sarcomas benefit from conventional chemotherapy, targeted therapy takes the most relevant role in the management of those resistant to or failed to conventional chemotherapy. Heterogeneous soft tissue sarcomas vary from biological behavior, genetic mutations, and clinical presentation with a low incidence, indicating the future direction of histotype-based even molecule-based personalized therapy. Furthermore, increasing preclinical studies were carried out to investigate the pathogenesis and potential therapeutic targets of soft tissue sarcomas and increasing new drugs have been developed in recent years, which had started opening new doors for clinical treatment for patients with advanced/metastatic soft tissue sarcomas. Here we sought to summarize the concise characteristics and advance in the targeted therapy for the most common subtypes of soft tissue sarcomas.
Insights
Targeted therapy offers new hope for advanced soft tissue sarcomas (STS) that resist conventional treatments. Research is advancing personalized, molecule-based therapies for these rare cancers.
Area of Science:
- Oncology
- Cancer Research
- Pharmacology
Background:
- Soft tissue sarcomas (STS) are rare, heterogeneous cancers with high recurrence and mortality rates.
- Current treatments like surgery and chemotherapy have limitations, especially for advanced or metastatic cases.
- Limited progress in conventional therapies highlights the need for novel treatment strategies.
Purpose of the Study:
- To summarize the characteristics of common soft tissue sarcoma subtypes.
- To review recent advancements in targeted therapy for STS.
- To explore the potential of personalized, molecule-based treatment approaches.
Main Methods:
- Review of preclinical studies on STS pathogenesis and therapeutic targets.
- Analysis of recent clinical developments in targeted drug discovery for STS.
- Synthesis of information on targeted therapy for common STS subtypes.
Main Results:
- Targeted therapy is crucial for patients with advanced/metastatic STS resistant to conventional chemotherapy.
- Emerging preclinical research is identifying new therapeutic targets and drugs.
- Personalized, histotype-based, and molecule-based therapies are the future direction for STS management.
Conclusions:
- Targeted therapies represent a significant advancement for managing advanced and metastatic soft tissue sarcomas.
- Continued research into pathogenesis and drug development is vital for improving patient outcomes.
- Personalized medicine approaches hold promise for overcoming the heterogeneity of STS.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy